文献速递肝病

Seladelpar治疗原发性胆汁性胆管炎患者3个月疗效与安全性:ENHANCE,一项3期随机安慰剂对照研究

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
PubMed 文献 · Hepatology · 2023-04-06

ENHANCE为3期研究,评估选择性PPARδ激动剂seladelpar对比安慰剂治疗对熊去氧胆酸应答不佳或不耐受的原发性胆汁性胆管炎患者。因同期NASH试验中出现错误安全性信号而提前终止,盲态下将主要和次要终点修订至第3个月。seladelpar 5 mg和10 mg分别有57.1%和78.2%患者达到主要终点,显著高于安慰剂组的12.5%(p<0.0001);10 mg组碱性磷酸酶正常化率27.3%(p<0.0001),并显著改善瘙痒。

要点

  • seladelpar 10 mg组78.2%达到主要生化复合终点,显著高于安慰剂组12.5%(p<0.0001)。
  • 10 mg组碱性磷酸酶正常化率27.3%(p<0.0001),5 mg组5.4%(p=0.08),安慰剂组0%。
  • 10 mg组瘙痒数字评定量表较安慰剂显著降低(-3.14 vs -1.55,p=0.02)。

核心结论

  • 对熊去氧胆酸应答不佳或不耐受的原发性胆汁性胆管炎患者,seladelpar 10 mg治疗显著改善肝脏生化指标和瘙痒。
  • seladelpar似安全且耐受良好。

研究设计与样本

  • ENHANCE为3期随机、安慰剂对照研究,患者按1:1:1随机接受口服seladelpar 5 mg(n=89)、10 mg(n=89)或安慰剂(n=87)每日一次(酌情联用熊去氧胆酸)。
  • 因同期NASH试验中出现错误安全性信号,ENHANCE提前终止;盲态下将主要和次要疗效终点修订至第3个月。

主要发现

  • 达到主要终点(碱性磷酸酶<1.67×正常上限且较基线下降≥15%且总胆红素≤正常上限)的患者比例:seladelpar 5 mg组57.1%、10 mg组78.2%,安慰剂组12.5%(p<0.0001)。
  • 第12个月碱性磷酸酶正常化率:seladelpar 5 mg组5.4%(p=0.08)、10 mg组27.3%(p<0.0001),安慰剂组0%。
  • 基线瘙痒数字评定量表评分≥4分的患者中,seladelpar 10 mg组第6个月瘙痒评分平均降低3.14,安慰剂组降低1.55(p=0.02)。
  • 丙氨酸氨基转移酶较安慰剂显著下降:seladelpar 5 mg组下降23.4%(p=0.0008)、10 mg组下降16.7%(p=0.03),安慰剂组下降4%。
  • 未发生与治疗相关的严重不良事件。

局限性

  • ENHANCE因同期NASH试验中出现错误安全性信号而提前终止。
  • 盲态下将主要和次要疗效终点修订至第3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDCA). APPROACH AND RESULTS: Patients were randomized 1:1:1 to oral seladelpar 5 mg (n=89), 10 mg (n=89), placebo (n=87) daily (with UDCA, as appropriate). Primary end point was a composite biochemical response [alkaline phosphatase (ALP) < 1.67×upper limit of normal (ULN), ≥15% ALP decrease from baseline, and total bilirubin ≤ ULN] at month 12. Key secondary end points were ALP normalization at month 12 and change in pruritus numerical rating scale (NRS) at month 6 in patients with baseline score ≥4. Aminotransferases were assessed. ENHANCE was terminated early following an erroneous safety signal in a concurrent, NASH trial. While blinded, primary and secondary efficacy end points were amended to month 3. Significantly more patients receiving seladelpar met the primary end point (seladelpar 5 mg: 57.1%, 10 mg: 78.2%) versus placebo (12.5%) ( p < 0.0001). ALP normalization occurred in 5.4% ( p =0.08) and 27.3% ( p < 0.0001) of patients receiving 5 and 10 mg seladelpar, respectively, versus 0% receiving placebo. Seladelpar 10 mg significantly reduced mean pruritus NRS versus placebo [10 mg: -3.14 ( p =0.02); placebo: -1.55]. Alanine aminotransferase decreased significantly with seladelpar versus placebo [5 mg: 23.4% ( p =0.0008); 10 mg: 16.7% ( p =0.03); placebo: 4%]. There were no serious treatment-related adverse events. CONCLUSIONS: Patients with primary biliary cholangitis (PBC) with inadequate response or intolerance to UDCA who were treated with seladelpar 10 mg had significant improvements in liver biochemistry and pruritus. Seladelpar appeared safe and well tolerated.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hirschfield GM, Shiffman ML, Gulamhusein A, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023. PMID: 37386786. doi:10.1097/HEP.0000000000000395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。